Philips(US:PHG) 智通财经网·2025-11-04 08:11Core Viewpoint - Philips reported a 2% year-over-year decline in Q3 sales to €4.302 billion, aligning with market expectations, while comparable sales grew by 3% [1][2]. Financial Performance - Adjusted EBITA for Q3 was €531 million, exceeding market expectations of €484 million [1]. - Adjusted earnings per share (EPS) increased to €0.36 [1][2]. - Net income rose to €187 million, with income from continuing operations at €188 million [2]. Business Segment Performance - Diagnostic and Treatment segment sales were €2.08 billion, with comparable sales growth of 1% [2]. - Connected Care segment sales reached €1.20 billion, showing a comparable sales growth of 5% [2]. - Personal Health segment sales amounted to €883 million, with a comparable sales growth of 11% [2]. Market and Strategic Insights - The U.S. remains Philips' largest market, and the company noted that the impact of tariffs would be less than expected due to a trade agreement between the EU and the U.S. [3]. - CEO Roy Jakobs emphasized the importance of investments in the supply chain to mitigate tariff impacts, stating that tariff costs detract from patient care investments [3]. - Philips reaffirmed its full-year guidance for 2025, expecting comparable sales growth of 1%-3% and an adjusted EBITA margin of 11.3%-11.8% [3].